Gómez Jorge, Tsagozis Panagiotis
Department of Orthopedic Surgery, Clínica Universidad de Navarra, University of Navarra, Pamplona 31008, Spain.
Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm 17176, Sweden.
World J Clin Oncol. 2020 Apr 24;11(4):180-189. doi: 10.5306/wjco.v11.i4.180.
Standard treatment for soft tissue sarcoma, based on complete surgical resection with or without adjuvant radiotherapy and chemotherapy, has not substantially changed during the last several decades. Nevertheless, recent advances have contributed to considerable improvement in the management of these patients; for example, new magnetic resonance imaging sequences such as diffusion-weighted imaging and magnetic resonance imaging radiomics can better assess tumor extension and even estimate its grade. Detection of circulating genetic material (liquid biopsy) and next-generation sequencing are powerful techniques for genetic analysis, which will increase our understanding of the underlying molecular mechanisms and may reveal potential therapeutic targets. The role of chemotherapy in non-metastatic disease is still controversial, and there is a need to identify patients who really benefit from this treatment. Novel chemotherapeutic regimens have entered clinical praxis and can change the outcome of patients with metastatic disease. Advances in radiotherapy have helped decrease local adverse effects and sustain good local control of the disease. The following report provides an updated view of the diagnosis, treatment, and future perspectives on the management of patients with soft tissue sarcomas.
基于完整手术切除并辅以或不辅以放疗及化疗的软组织肉瘤标准治疗方法，在过去几十年间并未发生实质性改变。然而，近期的进展已促使这些患者的管理有了显著改善；例如，新的磁共振成像序列，如扩散加权成像和磁共振成像放射组学，能够更好地评估肿瘤范围，甚至估计其分级。循环遗传物质检测（液体活检）和下一代测序是用于基因分析的强大技术，这将增进我们对潜在分子机制的理解，并可能揭示潜在的治疗靶点。化疗在非转移性疾病中的作用仍存在争议，有必要确定真正能从这种治疗中获益的患者。新型化疗方案已进入临床实践，可改变转移性疾病患者的治疗结果。放疗的进展有助于减少局部不良反应，并维持对疾病的良好局部控制。以下报告提供了关于软组织肉瘤患者管理的诊断、治疗及未来展望的最新观点。
